<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82265">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01862848</url>
  </required_header>
  <id_info>
    <org_study_id>Medimix Pharm-01</org_study_id>
    <nct_id>NCT01862848</nct_id>
  </id_info>
  <brief_title>Topical Compounded Pain Creams And Pain Perception (TOPCAPP)</brief_title>
  <acronym>TOPCAPP</acronym>
  <official_title>Topical Compounded Pain Creams And Pain Perception (TOPCAPP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medimix Specialty Pharmacy, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medimix Specialty Pharmacy, LLC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the change in patient pain perception with the use of a topical compounded pain
      cream regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective,observational,single center, open label study of patients that receive
      a combination topical compounded analgesic medication with no comparator group.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>12 Weeks</target_duration>
  <primary_outcome>
    <measure>Perceived pain changes</measure>
    <time_frame>12 Week Study [Baseline, 4,8, and 12 week evaluation]</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minimal sample size of 60 persons(maximum n=150)with a diagnosis of chronic pain (n=30 neuropathic and n=30 nociceptive primary pain-type)to determine predictors of a 30% or greater reduction of pain scores evaluated by logistic regression analyses utilizing the Brief Pain Index scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 Weeks [Baseline,4,8, and 12 week evaluation]</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the change in quality of life using the EuroQol-5D-3L survey.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pain</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with neuropathic or nociceptive chronic pain who are between 18 and 65 years
        of age prescribed a combination compounded topical analgesic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be diagnosed with an ICD9 code indicative of chronic pain.

          -  Participants must be starting a new regimen of topical therapy with multiple
             compounded agents.

          -  Participants must be expecting to receive therapy for at least 12 weeks.

          -  Participants must be between 18 and 65 years of age.

          -  Participants must be able to provide sound written and verbal informed consent.

        Exclusion Criteria:

          -  Participants must not have prior hypersensitivity or adverse events to any of the
             components in the customized prescription.

          -  Participants must not be pregnant or breastfeeding women.

          -  Participants must not have a diagnosis of cancer within the past 5 years.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin J Epstein, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Medimix Specialty Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Medimix Specialty Pharmacy, LLC</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA. 1998 Jul 8;280(2):147-51. Erratum in: JAMA 1998 Oct 7;280(13):1142.</citation>
    <PMID>9669787</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 28, 2013</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Topical Compounded Pain Creams and Pain Perception</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
